Sigma Planning Corp purchased a new stake in shares of UiPath Inc. (NYSE:PATH – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 32,550 shares of the healthcare company’s stock, valued at approximately $809,000.
Several other institutional investors also recently added to or reduced their stakes in PATH. HighMark Wealth Management LLC bought a new position in UiPath during the fourth quarter valued at about $27,000. Fifth Third Bancorp grew its position in UiPath by 2,005.3% during the third quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock valued at $34,000 after buying an additional 1,905 shares during the period. FNY Investment Advisers LLC bought a new position in UiPath during the fourth quarter valued at about $40,000. FSC Wealth Advisors LLC bought a new position in UiPath during the fourth quarter valued at about $43,000. Finally, Tennessee Valley Asset Management Partners bought a new position in UiPath during the fourth quarter valued at about $50,000. Institutional investors own 62.50% of the company’s stock.
UiPath Price Performance
Shares of UiPath stock opened at $19.54 on Wednesday. The business has a fifty day simple moving average of $22.55 and a two-hundred day simple moving average of $21.56. UiPath Inc. has a 12 month low of $12.38 and a 12 month high of $27.87.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the stock. Scotiabank increased their price target on shares of UiPath from $29.00 to $30.00 and gave the company a “sector perform” rating in a research report on Thursday, March 14th. Morgan Stanley raised their target price on shares of UiPath from $17.00 to $25.00 and gave the company an “equal weight” rating in a research note on Thursday, March 14th. William Blair assumed coverage on shares of UiPath in a research report on Tuesday, January 2nd. They set an “outperform” rating on the stock. Barclays increased their price target on shares of UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a research report on Friday, March 15th. Finally, Evercore ISI increased their price target on shares of UiPath from $24.00 to $27.00 and gave the company an “in-line” rating in a research report on Thursday, March 14th. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, UiPath has an average rating of “Moderate Buy” and an average price target of $27.41.
Check Out Our Latest Report on UiPath
Insider Transactions at UiPath
In other news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $21.66, for a total value of $866,400.00. Following the completion of the transaction, the chief financial officer now owns 660,762 shares of the company’s stock, valued at approximately $14,312,104.92. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 72,000 shares of company stock valued at $1,591,360 in the last quarter. 31.03% of the stock is owned by insiders.
UiPath Profile
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Featured Articles
- Five stocks we like better than UiPath
- Insider Buying Explained: What Investors Need to Know
- Packaging Corporation of America: Buy The Dip
- High Flyers: 3 Natural Gas Stocks for March 2022
- Duolingo Speaks the Language of Growth for Investors
- What is the Nikkei 225 index?
- United Parcel Service Is Setting Up for Another Fall
Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.